智通财经APP获悉，旺山旺水-B(02630)午后拉升逾15%，截至发稿，涨14.81%，报88港元，成交额 1333.12万港元。 消息面上，旺山旺水本月初发布公告，与先声药业就VV116新适应症订立许可协议。根据该协议，先声 药业将获得氢溴酸氘瑞米德韦干混悬剂在大中华区用于抗呼吸道合胞病毒（RSV）感染以及抗人偏肺病 毒（HMPV）感染适应症的独家许可权益。旺山旺水与先声药业强强联合，发挥各自研发、生产及商业 化的优势，加速VV116的临床开发和商业化进程，以期惠及更多患者。 公开资料显示，旺山旺水重点布局神经精神、生殖健康和病毒感染三大治疗领域。截至2025年10月21 日，公司已搭建多元化的9个创新管线，其中2个处于商业化阶段，4个处于临床阶段，3个处于临床前阶 段。除了创新药管线，公司还布局仿制药板块，其中3款药物处于商业化或接近商业化阶段。目前，旺 山旺水的两款核心产品分别是LV232和TPN171。 ...

Core Viewpoint - The collaboration between 旺山旺水-B and 先声药业 aims to accelerate the clinical development and commercialization of VV116 for new indications, specifically targeting RSV and HMPV infections in Greater China [1][2]. Group 1: Licensing Agreement - 旺山旺水-B has entered into a licensing agreement with 先声药业 for exclusive rights to develop VV116 for RSV and HMPV infections in Greater China [1]. - The partnership leverages the strengths of both companies in research, production, and commercialization to benefit more patients [1]. Group 2: Product Overview - VV116 is an oral nucleoside prodrug that received conditional approval from the National Medical Products Administration (NMPA) in January 2023 for treating mild to moderate COVID-19, with plans for full approval by January 2025 [1]. - VV116 has shown broad-spectrum antiviral activity against various RNA viruses, including RSV, demonstrating good inhibition effects [1]. Group 3: Clinical Trials and Safety - A Phase II clinical trial for VV116 as a treatment for RSV in infants has been completed, leading to its designation as a breakthrough therapy by NMPA [2]. - Preclinical studies indicate significant antiviral effects of VV116 in vitro and in animal models, along with improvements in lung pathology [2]. - Clinical pharmacokinetic studies show good oral absorption and linear pharmacokinetics, with no significant impact from infant formula on its main metabolites [2]. - Overall safety of VV116 in clinical studies is reported to be good, with no severe adverse events noted [2].

Core Viewpoint - The company has entered into a licensing agreement with Ascletis Pharma Inc. for the exclusive rights to develop and commercialize VV116 for RSV and HMPV infections in Greater China, aiming to accelerate clinical development and commercialization to benefit more patients [1][2]. Group 1: Licensing Agreement - The company grants Ascletis exclusive licensing rights for VV116 in the treatment of RSV and HMPV infections in Greater China [1]. - This collaboration leverages the strengths of both companies in research, production, and commercialization [1]. Group 2: Product Overview - VV116 is an oral nucleoside prodrug that received conditional approval from the National Medical Products Administration (NMPA) in January 2023 for treating mild to moderate COVID-19 infections, with plans for full approval by January 2025 [1]. - VV116 exhibits broad-spectrum antiviral activity, showing effective inhibition against various RNA viruses, including RSV [1]. Group 3: Clinical Trials and Safety - A Phase II clinical trial for VV116 as a treatment for RSV in infants has been completed, leading to its designation as a breakthrough therapy by the NMPA [2]. - Preclinical studies indicate significant antiviral effects of VV116 in vitro and in animal models, along with improvements in lung pathology [2]. - Clinical pharmacokinetic studies demonstrate good oral absorption and linear pharmacokinetics, with no significant impact from infant formula on its main metabolites [2]. - Overall safety in clinical studies is reported to be good, with no severe adverse events noted [2].

| HK + + = = B | | | | --- | --- | --- | | 02630 L2 ▼ | | | | 66 600 37 | 82.000 最高 82.000 最低 66 | | | 0.013% 总量 -18.78%-15 400 块子 | 8400股 金额 | 56. | | 总值 112.3亿 市盈 -49.19 市净 | 2.74 | Vm | | 分时 | 五日 日K 周K 月K 更多 | | | 均价:72.658 价格:66.600 -15.400 -18.78% | | | | 97.700 | 19.15% 卖1 66.950 | | | | 买1 66.550 分时成交 | 2 | | | 10:35 66.500 | | | | 10:35 66.5501 | | | | 10:35 66.600↑ | | | 87000 | 10:35 66.6501 | | | | 10:35 66.800↑ | | | | 10:36 67.000↑ | | | | 10:36 67.000 | | | | 10:36 67.050↑ | | | | 10:36 67.050 ...

Group 1 - The company Wangshan Wangshui-B (02630) has completed its subscription period from October 28 to November 3, 2025, with a total margin loan of at least HKD 279.7 billion, resulting in an oversubscription of 4,974 times against the public offering amount of HKD 59.83 million [1] - The company plans to issue 17.6 million shares, with 10% allocated for public offering, and the share price is set between HKD 32 to 34, aiming to raise up to nearly HKD 600 million [1][2] - Wangshan Wangshui is a biopharmaceutical company established in 2013, focusing on discovering, acquiring, developing, and commercializing small molecule drugs in strategic therapeutic areas, specifically neuropsychiatric and reproductive health [1] Group 2 - The company has not yet achieved profitability, recording a net loss of RMB 218 million in 2024, compared to a net profit of RMB 6.427 million in 2023, with the fluctuation attributed to a decline in revenue [2] - According to the prospectus, 38% of the net proceeds from the global offering will be allocated to the research and development of core products, 27% for other candidate products, 15% to enhance sales and marketing capabilities, 10% for building a factory in Qingdao, and 10% for other general corporate purposes [2]

Group 1 - The core viewpoint of the news is that the biopharmaceutical company Wangshan Wangshui-B (02630) has successfully completed its IPO subscription, achieving significant oversubscription and plans to list on November 6, 2025 [1][2] - The company has raised at least HKD 279.7 billion in margin financing, with a public offering amounting to HKD 59.83 million, resulting in an oversubscription rate of 4,974 times [1] - Wangshan Wangshui plans to issue 17.6 million shares, with 10% allocated for public offering, and the share price is set between HKD 32 to 34, aiming to raise nearly HKD 600 million [1] Group 2 - Wangshan Wangshui was established in 2013 and focuses on discovering, developing, and commercializing small molecule drugs in strategic therapeutic areas, specifically neuropsychiatric and reproductive health [1] - The company has developed a diversified pipeline of nine innovative assets, with two in commercialization, four in clinical stages, and three in preclinical stages [1] - The company reported a net loss of RMB 218 million in 2024, compared to a net profit of RMB 6.427 million in 2023, attributing the fluctuation to a decline in revenue [2] Group 3 - The company plans to allocate 38% of the net proceeds from the global offering to the research and development of core products, 27% for other candidate products, 15% to enhance sales and marketing capabilities, 10% for building a factory in Qingdao, and 10% for other general corporate purposes [2]

Group 1: Market Overview - The Hong Kong stock market showed a downward trend with the Hang Seng Index falling by 0.24%, the Hang Seng China Enterprises Index down by 0.31%, and the Hang Seng Tech Index decreasing by 0.68% [2] - The total market turnover was HKD 353.8 billion, with short selling amounting to HKD 56.37 billion, representing 17.74% of the total turnover [2] - Northbound capital saw a net inflow of HKD 13.641 billion, with the most actively traded stocks being the Tracker Fund of Hong Kong, Alibaba, and Meituan [2] Group 2: Company Overview - 旺山旺水 (Wangshan Wangshui) - 旺山旺水, established in 2013, is a biopharmaceutical company focusing on three therapeutic areas: neuropsychiatry, reproductive health, and viral infections [7] - As of October 21, 2025, the company has developed a diversified pipeline of nine innovative products, with two in commercialization, four in clinical stages, and three in preclinical stages [7] - The company's revenue primarily comes from licensing agreements, CRO services, and drug sales, with revenues of HKD 200 million, HKD 10 million, and HKD 10 million for 2023, 2024, and the first four months of 2025, respectively [7] Group 3: Industry Status and Outlook - The global neuropsychiatric drug market is projected to grow from USD 164.2 billion in 2018 to USD 201.5 billion in 2024, with a CAGR of 3.5%, and expected to reach USD 251.0 billion by 2035 [8] - The reproductive health drug market in China is anticipated to increase from CNY 29.4 billion in 2018 to CNY 36.2 billion in 2024, with a CAGR of 3.5%, and further to CNY 42.2 billion by 2035 [8] - The antiviral drug market in China is expected to grow from CNY 20.3 billion in 2024 to CNY 40.3 billion by 2035, with a CAGR of 6.4%, while the global antiviral drug market is projected to rise from USD 67.7 billion in 2018 to USD 102.7 billion in 2024, with a CAGR of 7.2% [8] Group 4: Strengths and Opportunities - The company has two core products, including VV116, which has shown excellent efficacy and broad indications, being the only product fully approved for COVID-19 treatment [9] - The proprietary technology platform enhances the company's strong internal R&D capabilities, driving continuous innovation [9] - The management team possesses extensive experience in the industry [9] Group 5: IPO Information - The IPO subscription period is from October 28 to November 3, with the listing date set for November 6 [11] - Approximately 38% of the raised funds will be allocated to core product development, 27% to other candidate product development, 10% for building a factory in Qingdao, 15% to enhance sales and marketing capabilities, and 10% for operational funds and other general corporate purposes [12] Group 6: Investment Recommendation - 旺山旺水 has two drugs on the market, with VV116 being the only fully approved product for COVID-19 treatment, reflecting strong R&D capabilities [13] - If priced at the upper limit of HKD 34, the company's market capitalization upon listing would be approximately HKD 5.7 billion [13] - Considering the company's industry position, underwriters, and the hot IPO market for pharmaceuticals in Hong Kong, an IPO score of 6.1 is assigned, recommending subscription [13]

蘇州旺山旺水生物醫藥股份有限公司 Vigonvita Life Sciences Co., Ltd. 股份代號 : 2 6 3 0 （於中華人民共和國註冊成立的股份有限公司） 全球發售 獨家保薦人、保薦人兼整體協調人、整體協調人、 聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 聯席賬簿管理人及聯席牽頭經辦人（按英文字母順序排列） 重要提示 重要提示： 閣下對本招股章程的任何內容如有任何疑問，應獲取獨立專業意見。 Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 | 全球發售的發售股份數目 | ： | 17,597,800股H股（視乎 | | --- | --- | --- | | | | 超額配股權行使情況而定） | | 香港發售股份數目 | ： | 1,759,800股H股（可予重新分配） | | 國際發售股份數目 | ： | 15,838,000股H股（可予重新分配及 | | | | 視乎超額配股權行使與否而定） | | 最高發售價 | ： ...

Core Viewpoint - The company, Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd., has passed the listing hearing on the Hong Kong Stock Exchange, focusing on three major therapeutic areas: neuropsychiatry, reproductive health, and viral infections, with two of its nine innovative assets already commercialized [1][3]. Market Potential - The Chinese markets for antiviral drugs, neuropsychiatric drugs, and reproductive health drugs are projected to grow significantly, with estimates of RMB 1,235 billion, RMB 422 billion, and RMB 403 billion respectively by 2035, indicating substantial market opportunities despite the challenges in developing successful therapies [3][4]. Financial Performance - The company's financial performance has shown significant volatility, with revenues of RMB 200 million in 2023 dropping to RMB 11.83 million in 2024, alongside a net loss of RMB 218 million in 2024 compared to a net profit of RMB 6.43 million in 2023 [4][5][6]. Revenue Sources - Revenue sources are diversified, including licensing agreements and CRO services, but the reliance on one-time licensing income from VV116 has raised concerns about sustainable revenue generation [4][6]. R&D Investment - The company maintains high R&D expenditures, with RMB 1.31 billion and RMB 1.35 billion spent in 2023 and 2024 respectively, reflecting the industry's focus on innovation but also contributing to significant losses [6][10]. Cash Flow Situation - The operating cash flow has dramatically shifted from an inflow of RMB 47.37 million in 2023 to an outflow of RMB 150.59 million in 2024, indicating severe cash consumption and raising concerns about the company's long-term operational sustainability [7][9]. Product Pipeline - The company has developed nine innovative assets, with two in commercialization and four in clinical stages, necessitating substantial funding to support ongoing clinical trials and product development [6][10]. TPN171 Product Analysis - TPN171, a new generation PDE5 inhibitor, targets the growing erectile dysfunction market, which is expected to reach RMB 15 billion by 2035, with TPN171 showing significant clinical advantages over existing treatments [11][13]. Competitive Landscape - The PDE5 inhibitor market in China is characterized by a "three-legged" competition among existing products, indicating both opportunities and challenges for TPN171 as it seeks to establish its market presence [13][14]. Investment Considerations - Key questions for investors include the market penetration potential of TPN171, the sustainability of the company's cash reserves until other pipelines realize value, and the management's ability to balance R&D investment with a viable business model [14].

Core Viewpoint - The company, Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd., is set to list on the Hong Kong Stock Exchange, focusing on three major therapeutic areas: neuropsychiatry, reproductive health, and viral infections, with a pipeline of nine innovative assets, two of which are in commercialization [1][3]. Market Potential - The Chinese markets for antiviral drugs, neuropsychiatric drugs, and reproductive health drugs are projected to grow significantly, with estimates of RMB 1,235 billion, RMB 422 billion, and RMB 403 billion respectively by 2035, indicating substantial growth opportunities [3][4]. - The reproductive health drug market is expected to nearly double in size over the next decade, highlighting a particularly strong growth trajectory [3]. Financial Performance - The company's financial performance has shown significant volatility, with revenues of RMB 200 million in 2023 dropping to RMB 11.83 million in 2024, and a net loss of RMB 218 million in 2024 compared to a net profit of RMB 6.43 million in 2023 [4][5]. - Revenue sources are diverse, including licensing agreements and CRO services, but reliance on one-time licensing income has raised concerns about sustainable revenue generation [4][6]. Research and Development - R&D expenditures remain high, with RMB 1.31 billion and RMB 1.35 billion spent in 2023 and 2024 respectively, reflecting the industry's emphasis on innovation despite the financial downturn [6][10]. - The company has developed nine innovative assets, with two in commercialization, four in clinical stages, and three in preclinical stages, necessitating substantial funding [6][10]. Cash Flow Situation - The company's cash flow has experienced dramatic fluctuations, with operating cash flow shifting from an inflow of RMB 47.37 million in 2023 to an outflow of RMB 151 million in 2024, indicating severe cash consumption [7][9]. - Cash reserves are rapidly depleting, with a notable decrease in cash and cash equivalents, raising concerns about the company's ability to sustain operations without new financing [9][10]. Product Analysis - TPN171, a core product, targets the erectile dysfunction market, which is projected to reach RMB 15 billion by 2035, with a significant compound annual growth rate [11][13]. - TPN171 demonstrates clinical advantages, including a lower effective dose compared to competitors, which may enhance its market positioning [13]. Investment Considerations - Key questions for investors include whether TPN171 can gain market traction, if the company's cash reserves can support ongoing operations until other pipelines mature, and whether management can balance R&D investment with sustainable business models [14].